Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) - a randomized controlled trial. The efficacy of cabergoline on tumour volume in previously untreated macroadenomas or residual adenomas after pituitary surgery or irradiation. - Dopamine agonist treatment of non-functioning pituitary adenomas

St. Olavs Hospital Trondheim University Hospital0 sites80 target enrollmentMay 10, 2012

Overview

No summary available.

Registry

who.int

Start Date

May 10, 2012

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

St. Olavs Hospital Trondheim University Hospital

•1\.A previously untreated non\-functioning pituitary macroadenoma (largest diameter \= 10 mm) OR a residual tumour after surgical treatment of a non\-functioning pituitary macroadenoma
•2\.Age 18\-75 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 45
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range 35

•1\.Clear indication for surgery at the time of inclusion
•2\.Radiation therapy the last 2 years prior to inclusion, or radiation therapy \>2 years earlier if significant tumour shrinkage after treatment
•3\.Pituitary surgery the last 6 months
•4\.Apoplexy/bleeding in the adenoma
•5\.Pregnancy or lactation
•6\.Contraindications for cabergoline treatment:
•Known cardiac valvular disease
•Known pulmonal, pericardial or retroperitoneal fibrosis
•Clinical significant liver insufficiency
•Use of medications that interact with cabergoline